Proton Therapy for Prostate Cancer: Challenges and Opportunities
The dosimetric advantages of proton therapy (PT) treatment plans are demonstrably superior to photon-based external beam radiotherapy (EBRT) for localized prostate cancer, but the reported clinical outcomes are similar. This may be due to inadequate dose prescription, especially in high-risk disease...
Main Authors: | Darren M. C. Poon, Stephen Wu, Leon Ho, Kin Yin Cheung, Ben Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/4/925 |
Similar Items
-
Insurance Approval for Definitive Proton Therapy for Prostate Cancer
by: William M. Mendenhall, MD, et al.
Published: (2021-07-01) -
Consensus Statement on Proton Therapy for Prostate Cancer
by: Curtis M. Bryant, MD, MPH, et al.
Published: (2021-04-01) -
Ultra-Hypofractionated Proton Therapy in Localized Prostate Cancer: Passive Scattering versus Intensity-Modulated Proton Therapy
by: Dorota Maria Borowicz, et al.
Published: (2021-12-01) -
Proton versus photon therapy for high-risk prostate cancer with dose escalation of dominant intraprostatic lesions: a preliminary planning study
by: Ashley Li Kuan Ong, et al.
Published: (2023-11-01) -
The Role of Proton Therapy for Prostate Cancer in the Setting of Hip Prosthesis
by: Maryam Moteabbed, et al.
Published: (2024-01-01)